Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434375 | 0.87 | KDM4E (0.53) | ATMSLC6A3MEN1POLBKMT2A | |
| SCHEMBL11863807 | 0.87 | KDM4E (0.53) | ATMSLC6A3MEN1POLBKMT2A | |
| SCHEMBL19857212 | 0.87 | KDM4E (0.53) | ATMSLC6A3MEN1POLBKMT2A | |
| SCHEMBL16785349 | 0.87 | KDM4E (0.53) | ATMSLC6A3MEN1POLBKMT2A | |
| SCHEMBL28530032 | 0.86 | FPR1 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL20411542 | 0.86 | FPR1 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL20411539 | 0.86 | FPR1 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7736125 | 0.85 | MAPT (0.56) | MEN1KMT2A | |
| SCHEMBL7278537 | 0.79 | SLC6A4 (0.50) | ATMSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3649072 | 0.76 | SLC6A3 (0.49) | ATMSLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| EP-1983993-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007092364-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | ATM 3446/4885SLC6A3 651/4885SLC6A4 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.